94,291 Shares in GW Pharmaceuticals PLC- (GWPH) Purchased by Axa

AXA bought a new stake in shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 94,291 shares of the biopharmaceutical company’s stock, valued at approximately $9,570,000. AXA owned approximately 0.37% of GW Pharmaceuticals PLC- as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in GWPH. Royal Bank of Canada grew its stake in GW Pharmaceuticals PLC- by 0.4% during the 2nd quarter. Royal Bank of Canada now owns 4,240 shares of the biopharmaceutical company’s stock valued at $424,000 after purchasing an additional 18 shares during the last quarter. IHT Wealth Management LLC grew its stake in GW Pharmaceuticals PLC- by 18.0% during the 2nd quarter. IHT Wealth Management LLC now owns 656 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 100 shares during the last quarter. Advisor Group Inc. grew its stake in GW Pharmaceuticals PLC- by 10.7% during the 2nd quarter. Advisor Group Inc. now owns 1,500 shares of the biopharmaceutical company’s stock valued at $130,000 after purchasing an additional 145 shares during the last quarter. Ameriprise Financial Inc. grew its stake in GW Pharmaceuticals PLC- by 8.5% during the 2nd quarter. Ameriprise Financial Inc. now owns 2,064 shares of the biopharmaceutical company’s stock valued at $207,000 after purchasing an additional 162 shares during the last quarter. Finally, Raymond James Financial Services Advisors Inc. grew its stake in GW Pharmaceuticals PLC- by 18.6% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 3,700 shares of the biopharmaceutical company’s stock valued at $376,000 after purchasing an additional 581 shares during the last quarter. 74.57% of the stock is owned by hedge funds and other institutional investors.

A number of analysts have recently commented on GWPH shares. Cantor Fitzgerald set a $208.00 target price on GW Pharmaceuticals PLC- and gave the stock a “buy” rating in a research note on Monday, December 4th. Bank of America lowered their price target on GW Pharmaceuticals PLC- from $160.00 to $158.00 and set a “buy” rating on the stock in a research report on Tuesday, November 14th. Goldman Sachs Group upgraded GW Pharmaceuticals PLC- from a “neutral” rating to a “buy” rating and set a $174.00 price target on the stock in a research report on Thursday, December 14th. Zacks Investment Research downgraded GW Pharmaceuticals PLC- from a “hold” rating to a “sell” rating in a research report on Tuesday, December 26th. Finally, BidaskClub raised GW Pharmaceuticals PLC- from a “hold” rating to a “buy” rating in a report on Friday, December 22nd. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $148.78.

GW Pharmaceuticals PLC- (NASDAQ GWPH) traded down $0.56 on Friday, hitting $131.97. The stock had a trading volume of 189,050 shares, compared to its average volume of 428,093. The stock has a market capitalization of $3,350.00, a price-to-earnings ratio of -18.72 and a beta of 2.65. GW Pharmaceuticals PLC- has a 1-year low of $92.65 and a 1-year high of $140.52. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.47 and a current ratio of 7.59.

TRADEMARK VIOLATION WARNING: This piece was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/01/13/axa-invests-9-57-million-in-gw-pharmaceuticals-plc-gwph.html.

GW Pharmaceuticals PLC- Profile

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Institutional Ownership by Quarter for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply